Crizotinib Achieves Long-Lasting Disease Control in Advanced Papillary RCC Type 1 With MET Mutations or Amplification
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Crizotinib Achieves Long-Lasting Disease Control in Advanced Papillary Renal-Cell Carcinoma Type 1 Patients With MET Mutations or Amplification. EORTC 90101 CREATE Trial
Eur. J. Cancer 2017 Nov 14;87(xx)147-163, P Schöffski, A Wozniak, B Escudier, P Rutkowski, A Anthoney, S Bauer, J Sufliarsky, C van Herpen, LH Lindner, V Grünwald, B Zakotnik, E Lerut, M Debiec-Rychter, S Marréaud, M Lia, T Raveloarivahy, S Collette, L AlbigesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.